While increased sweating is not listed as a common side effect of semaglutide in the SmPC, patients taking Ozempic alongside insulin or sulfonylureas should be aware that sweating can be a symptom of hypoglycaemia
However, some may find that their weight loss allows them to be more active and exercise daily, which is a known factor in preventing weight re-gain
Understanding how to mix peptides with bacteriostatic water properly is essential for anyone using reconstituted formulations
Ozempic is primarily approved for type 2 diabetes (and cardiovascular risk reduction in certain adults with type 2 diabetes), while Wegovy is approved for chronic weight management in eligible patients
However, because we have determined that the cost of reporting on these measures outweighs the benefits of retaining them in the program, it would place an undue burden on hospitals and ASCs to continue requiring reporting on these measures for an additional year
Current Pharmaceutical Design, 24(18), 1947-1956
